Skip to main content
SpringerLink
Log in
Book cover

Gynecologic Oncology pp 277–285Cite as

High-dose chemotherapy in gynecologic malignancies

  • Chapter

Part of the book series: Cancer Treatment and Research ((CTAR,volume 95))

Abstract

Of all the gynecologic malignancies, ovarian cancer has been the most extensively studied in hematopoietic cell-supported high-dose chemotherapy trials. This strategy has not been tested in patients with cervical, endometrial, or vulvar carcinoma, other than their rare inclusion in phase I trials. Therefore, for the purposes of this review, we focus on the high-dose chemotherapy studies of ovarian cancer.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   429.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   549.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   549.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ozols RF (1994) Treatment of ovarian cancer: Current status. Semin Oncol 21:1–9.

    PubMed  CAS  Google Scholar 

  2. McGuire WP, Hoskins WJ, Brady MF, et al. (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1–6.

    Article  PubMed  CAS  Google Scholar 

  3. Behrens BC, Hamilton TC, Masuda H, et al. (1987) Chracteristics of cisdiamminedo-chloroplatinum (II)-resistant human ovarian cancer cell line and its evaluation of platinum analogues. Cancer Res 47:414–418.

    PubMed  CAS  Google Scholar 

  4. Lidor YJ, Shpall EJ, Peters WP, Bast RC (1991) Synergistic cytotoxicity of different alkylating agents for epithelial ovarian cancer. Int J Cancer 49:704–710.

    Article  PubMed  CAS  Google Scholar 

  5. Levin L, Hryniuk WM (1987) Dose-intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 5:756–767.

    PubMed  CAS  Google Scholar 

  6. Bruckner H, Wallach R (1981) High-dose platinum for the treatment of refractory ovarian carcinoma. Gynecol Oncol 12:64–67.

    Article  PubMed  CAS  Google Scholar 

  7. Ozols R, Ostchega Y, Myers C, et al. (1985) High-dose cisplatin in hypertonic saline in refractory ovarian cancer. J Clin Oncol 3:1246–1250.

    PubMed  CAS  Google Scholar 

  8. Barker GH, Wiltshaw E (1981) Use of high dose cisplatin following failure of previous chemotherapy for advanced carcinoma of the ovary. Br J Obstet Gynaecol 88:1192–1199.

    Article  PubMed  CAS  Google Scholar 

  9. Ngan H, Choo Y, Cheung M, et al. (1989) A randomized study of high-dose versus low-dose cisplatinum combined with cyclophosphamide in the treatment of advanced ovarian cancer. Chemotherapy 35:221–227.

    Article  PubMed  CAS  Google Scholar 

  10. Conte P, Bruzzone M, Camino F, et al. (1996) High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: A randomized study of the Gruppo Oncologico Nord-Ouest. J Clin Oncol 14:351–356.

    PubMed  CAS  Google Scholar 

  11. McGuire WP, Hoskins W, Brady M, et al. (1995) Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: A Gynecologic Oncology Group + study. J Clin Oncol 13:1589–1599, 1995.

    PubMed  CAS  Google Scholar 

  12. Gore M, Mainwaring P, Macfarlane V, et al. (1996) A randomized study of high versus standard dose carboplatin in patients with advanced ovarian cancer. Proc Am Soc Clin Oncol 15:284 (abstract).

    Google Scholar 

  13. Dittrich C, Obermair A, Kurz C, et al. (1996) Prospective randomized trial of cisplatin/ carboplatin versus conventional cisplatin/cyclophosphamide in epithelial ovarian cancer: First results of the impact of platinum dose-intensity on patient outcome. Proc Am Soc Clin Oncol 15:279 (abstract).

    Google Scholar 

  14. Kaye S, Paul J, Cassidy J, et al. (1996). Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. J Clin Oncol 14:2113–2119, 1996.

    PubMed  CAS  Google Scholar 

  15. Jakobsen A, Bertelsen K, Andersen JE, et al. (1997) Dose-effect study of carboplatin in ovarian cancer: A Danish Ovarian Cancer Group Study. J Clin Oncol 15:193–198.

    PubMed  CAS  Google Scholar 

  16. Shpall EJ, Clarke-Pearson D, Soper T, et al. (1990) High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer. Gynecol Oncol 38:386–391.

    Article  PubMed  CAS  Google Scholar 

  17. Shpall EJ, Jones RB, Bearman SI, et al. (1994) Future strategies for the treatment of advanced epithelial ovarian cancer using high-dose chemotherapy and autologous bone marrow support. Gynecol Oncol 54:357–361.

    Article  PubMed  CAS  Google Scholar 

  18. Alberts DS, Young L, Mason N, et al. (1985) In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration. Semin Oncol 12:38–42.

    PubMed  CAS  Google Scholar 

  19. Stiff PJ, McKenzie RS, Alberts SD, et al. (1994) Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue: High response rate for refractory ovarian carcinoma. J Clin Oncol 12:176–183.

    PubMed  CAS  Google Scholar 

  20. Stiff PJ, Bayer R, Camarda M, et al. (1995) A phase II trial of high-dose mitoxantrone, carboplatin and cyclophosphamide with autologous bone marrow rescue for recurrent epithelial ovarian carcinoma: Analysis of risk factors for clinical outcome. Gynecol Oncol 57:278–285.

    Article  PubMed  CAS  Google Scholar 

  21. Stiff PJ, Bayer R, Kerger C, et al. (1997) High dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: A multivariate analysis for 100 consecutively treated patients. J Clin Oncol 15:1309–1317.

    PubMed  CAS  Google Scholar 

  22. Shea TC, Storniolo AM, Mason JR, et al. (1992) High-dose IV and IP combination chemotherapy with autologous stem cell rescue for patients eith advanced ovarian cancer. Proc Annu Meet Soc Clin Oncol 11:A756.

    Google Scholar 

  23. Broun ER, Belinson JL, Berek JS, et al. (1994) Salvage therapy for recurrent and refractory ovarian cancer with high-dose chemotherapy and autologous bone marrow support: A Gynecologic Oncology Group pilot study. Gynecol Oncol 54:142–146.

    Article  PubMed  CAS  Google Scholar 

  24. Moulder PO, Sleijfer D, Willemse P, et al. (1989) High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors. Cancer Res 49:4654–4658.

    Google Scholar 

  25. Viens P, Gravis G, Blaise D, et al. (1995) High dose chemotherapy with bone marrow rescue for patients with FIGO stage III or IV common epithelial ovarian carcinoma responding to first line treatment. Proc Annu Meet Am Soc Clin Oncol 14:A811.

    Google Scholar 

  26. Legros M, Dauplat J, Fleury J, et al. (1997) High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: Long-term results. J Clin Oncol 15:1302–1308.

    PubMed  CAS  Google Scholar 

  27. Viens P, Maraninchi D, Legros M, et al. (1990) High dose melphalan and autologous marrow rescue in advanced epithelial ovarian carcinomas: A retrospective analysis of 35 patients treated in France. Bone Marrow Transpl 5:227–233.

    CAS  Google Scholar 

  28. Benedetti-Panici P, Greggi S, Scambia G, et al. (1995) Very high-dose chemotherapy with autologous peripheral stem cell support in advanced ovarian cancer. Eur J Cancer 31A:1987–1992.

    Article  PubMed  CAS  Google Scholar 

  29. Lotz P, Bouleuc C, Andre T, et al. (1996) Tandem high-dose chemotherapy with ifosfamide, carboplatin and teniposide with autologous bone marrow transplantation for the treatment of poor prognosis common epithelial ovarian carcinoma. Cancer 77:2550–2559.

    Article  PubMed  CAS  Google Scholar 

  30. Langleben A, Ahlgren P, Stanimir G, et al. (1995) Dose intensification and autologous bone marrow transplantation as initial therapy of ovarian cancer. Proc Am Assoc Cancer Res 36:A1210.

    Google Scholar 

  31. Extra JM, Dieras V, Giacchetti S, et al. (1992) High-dose chemotherapy with autologous bone marrow reinfusion as consolidation therapy for patients with advanced ovarian adenocarcinoma. Proc Am Soc Clin Oncol 11:A749.

    Google Scholar 

  32. Moulder PO, Willemse P, Aalders J, et al. (1989) High-dose chemotherapy with autologous bone marrow transplantation in patients with refractory ovarian cancer. Eur J Cancer Clin Oncol 25:645–649.

    Article  Google Scholar 

  33. Juttner CA, Davy MLJ, To LB, et al. (1992) Autologous PBSC transplantation in stage 3 and 4 ovarian cancer. Int J Cell Cloning 10(Suppl 1):145.

    Article  Google Scholar 

  34. Rebollo J, Henriquez I, Martin Algarra S, et al. (1991) High dose combination of carboplatin and etoposide followed by peripheral blood stem cell transplantation in the treatment of ovarian carcinoma. Proc Am Assoc Cancer Res 32:A1025.

    Google Scholar 

  35. Murakami M, Shinosuka T, Kuroshima Y, et al. (1994) High dose chemotherapy with autologous bone marrow transplantation for the treatment of malignant ovarian tumors. Semin Oncol 2(Suppl 1):29–32.

    Google Scholar 

Download references

Authors
  1. Yago Nieto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pablo J. Cagnoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elizabeth J. Shpall
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA

    Robert F. Ozols M.D., Ph.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media New York

About this chapter

Cite this chapter

Nieto, Y., Cagnoni, P.J., Shpall, E.J. (1998). High-dose chemotherapy in gynecologic malignancies. In: Ozols, R.F. (eds) Gynecologic Oncology. Cancer Treatment and Research, vol 95. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5447-9_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-5447-9_10

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7487-9

  • Online ISBN: 978-1-4615-5447-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation